21st Oct 2026 16:22
(Alliance News) - GSK PLC on Wednesday noted five-year data for ViiV Healthcare's HIV treatment Cabenuva, which the lead study author found "highly encouraging".
The London-based pharmaceutical company noted a study that showed 77% of participants remained in care and on long-acting HIV treatment Cabenuva with a median treatment duration of 18 months.
Furthermore, 94% of individuals who switched to Cabenuva had a last viral load of less than 50 copies per millilitre of blood plasma, while 81% maintained continuous viral suppression with only 1% experiencing confirmed virologic failure.
Ricky Hsu, lead study author, said: "By evaluating nearly 7,000 individuals in routine clinical care, this analysis gathered over the five-year OPERA study adds to and strengthens the clinical and real-world evidence base for long-acting cabotegravir and rilpivirine.
"The data offer vital, highly encouraging insights around treatment persistence with the long-acting therapy, showing that overall discontinuations were low and not commonly attributed to a lack of therapeutic efficacy or injection site pain. These are important insights for healthcare providers as they consider the full breadth of treatment options available to their patients."
Jean van Wyk, chief medical officer at ViiV Healthcare, said: "Long-term, real-world evidence is critical to help us better understand the impact of HIV treatment outside of the clinical trial setting.
"In this analysis gathered over five years from the OPERA cohort, cabotegravir and rilpivirine demonstrated durable and consistent viral suppression within a large and diverse patient population, with high persistence in routine care."
The findings will be shown at IDWeek 2026 in Washington DC between Wednesday and Saturday.
GSK shares were 0.3% higher at 1,874.00 pence each on Wednesday afternoon in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline